基于非小细胞肺癌（NSCLC）患者的铂类化疗药物的药物遗传学的荟萃分析。

Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.

机构信息

Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China.

出版信息

PLoS One. 2012;7(6):e38150. doi: 10.1371/journal.pone.0038150. Epub 2012 Jun 26.

AIM

To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients.

METHODS

Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI).

RESULTS

Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients.

CONCLUSION

Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.

目的

确定非小细胞肺癌（NSCLC）患者铂类化疗的药物遗传学。

方法

从 PubMed、Cochrane 图书馆和 ISI Web of Knowledge 中选择出版物。通过检查比值比（OR）和 95%置信区间（CI），进行荟萃分析以确定遗传多态性与基于铂类的化疗之间的关联。

结果

从 24 篇出版物中提取了数据，其中包括 8 个基因中的 11 个基因多态性进行荟萃分析。MDR1 C3435T（OR = 1.97，95%CI：1.11-3.50，P = 0.02）、G2677A/T（OR = 2.61，95%CI：1.44-4.74，P = 0.002）和 GSTP1 A313G（OR = 0.32，95%CI：0.17-0.58，P = 0.0002）与亚洲 NSCLC 患者的基于铂类化疗显著相关。